Waldenström macroglobulinemia

Synonyms
Waldenström disease, macroglobulinemia, lymphoplasmacytic lymphoma, IgM gammopathy
Specialty
Internal medicine · Haematology & oncology
Images
Clinical 1 · Blood smear & cytology 1
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Occurrence & epidemiology
  4. Aetiopathogenesis
  5. Clinical features
  6. Diagnosis
  7. Treatment principles
  8. Keep learning in the app
  9. Further reading (open access)
  10. Cross-references

Images (2)

Waldenström macroglobulinemia – chart: Serum protein electrophoresis tracing in Waldenström macroglobulinemia: tall, narrow-based M-spike in the γ region (monoclonal IgM-κ according to the authors)
Serum protein electrophoresis tracing in Waldenström macroglobulinemia: tall, narrow-based M-spike in the γ region (monoclonal IgM-κ according to the authors)Image: Xu L, Shen C, Mi J, Hu Z, Sheng Q, Zhu P, Song Z, Zhou F (Front Med 2026) (PubMed Central) · CC BY 4.0 · Source · modified (cropped)
Waldenström macroglobulinemia – Blood smear in Waldenström macroglobulinemia: rouleaux formation of red cells, small atypical lymphocytes and plasmacytoid cellsBlood smear & cytology
Blood smear in Waldenström macroglobulinemia: rouleaux formation of red cells, small atypical lymphocytes and plasmacytoid cellsImage: Charakidis M, Russell DJ, “Spontaneous splenic rupture in Waldenstrom's macroglobulinemia: a case report” (J Med Case Rep 2010) (PubMed Central) · CC BY 2.0 · Source
1 / 2

Definition

Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma with bone marrow infiltration and production of a monoclonal IgM paraprotein. Clinically, the disease resembles an indolent lymphoma more than multiple myeloma; osteolytic lesions are usually absent. After myeloma, it is the second most common malignant disorder associated with a monoclonal gammopathy.

Occurrence & epidemiology

The disease is uncommon. The median age at diagnosis is about 70 years; men are affected more often than women.

Aetiopathogenesis

The cause is unknown. The hallmark mutation is MYD88 L265P in more than 90 % of lymphoplasmacytic lymphomas; CXCR4 mutations are found in up to about 40 %. IgM MGUS frequently precedes the disease. The large IgM pentamer increases plasma viscosity; some IgM paraproteins act as rheumatoid factors or cold agglutinins, and about 10 % are cryoglobulins. Amyloidosis occurs in about 5 %.

Clinical features

  • Many patients are asymptomatic; diagnosis is often an incidental finding of IgM gammopathy.
  • Anemia with fatigue and weakness.
  • Hyperviscosity syndrome: fatigue, skin and mucosal bleeding, visual disturbances, headache, peripheral neuropathy, and changing neurologic deficits; increased plasma volume may precipitate heart failure.
  • Fundus: sausage-like engorged, segmentally narrowed retinal veins; later retinal hemorrhages, exudates, microaneurysms, and papilledema.
  • Lymphadenopathy, hepatosplenomegaly, purpura.
  • Cold sensitivity, Raynaud syndrome, recurrent bacterial infections.

Diagnosis

  • Protein studies: serum electrophoresis showing an M-protein, immunofixation (IgM; in urine often monoclonal light chains, mostly kappa), quantitative immunoglobulins (normal immunoglobulins reduced in half of patients), free light chains.
  • Blood count: moderate normocytic, normochromic anemia, marked rouleaux formation, very high ESR; occasionally leukopenia, relative lymphocytosis, thrombocytopenia.
  • Cryoglobulins, rheumatoid factor, cold agglutinins, direct Coombs test, coagulation studies; cold agglutinins and cryoglobulins may distort routine values.
  • Plasma viscosity: with hyperviscosity usually > 4.0 mPa·s (normal 1.4–1.8); additionally retinal fluorescein angiography.
  • Bone marrow examination: increase in plasma cells, lymphocytes, plasmacytoid lymphocytes, and mast cells; detection of MYD88 and CXCR4 mutations. Lymph node biopsy if the bone marrow is unremarkable.

Treatment principles

  • Asymptomatic disease is monitored without treatment; therapy is indicated for symptoms such as hyperviscosity, cytopenias, B symptoms, neuropathy or organ involvement.
  • Hyperviscosity syndrome is treated acutely with plasmapheresis.
  • Systemic options include anti-CD20 antibodies combined with chemotherapy, or BTK inhibitors; with high IgM levels, antibody therapy is started cautiously because of a possible IgM flare.

Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.

Keep learning in the app

In the InnereFuchs app you can learn Waldenström macroglobulinemia with flashcards, exam questions and image tasks (ECG, chest X-ray, ultrasound, lab values) – free, in your browser or as an app.

Open in browser  About InnereFuchs →

Further reading (open access)

  1. MSD Manual Professional: Macroglobulinemia
  2. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.

Related pages: Anemia (classification and work-up) · Hemolytic anemias · Acute myeloid leukemia (AML)

Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.